Dyslipidemia in Type 2 Diabetes (0767-034)

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type II; Dyslipidemia

• Registration Number: NCT00547274
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-19
• Study First Submitted QC: 2007-10-19
• Study First Posted: 2007-10-22
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-11
• Last Update Posted: 2015-06-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 111

Inclusion Criteria

• Men and non-pregnant females
• Age greater than or equal to 21 years
• Stop current diabetes therapy (if applicable)
• Stop current statin therapy (if applicable)

Read More

Exclusion Criteria

• History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
• Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
• Patients requiring treatment with corticosteroids for more than 14 consecutive days
• Patients taking warfarin or warfarin-like anti-coagulants
• Patients undergoing surgery within 30 days of Visit 1
• Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
• Patients with history of pancreatitis or uncontrolled high blood pressure

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL